IL205182A0 - Inhalation compositions comprising montelukast acid and a pde - 4 inhibitor or an inhaled corticosteroid - Google Patents

Inhalation compositions comprising montelukast acid and a pde - 4 inhibitor or an inhaled corticosteroid

Info

Publication number
IL205182A0
IL205182A0 IL205182A IL20518210A IL205182A0 IL 205182 A0 IL205182 A0 IL 205182A0 IL 205182 A IL205182 A IL 205182A IL 20518210 A IL20518210 A IL 20518210A IL 205182 A0 IL205182 A0 IL 205182A0
Authority
IL
Israel
Prior art keywords
pde
inhibitor
inhaled corticosteroid
montelukast acid
inhalation compositions
Prior art date
Application number
IL205182A
Other languages
English (en)
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of IL205182A0 publication Critical patent/IL205182A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL205182A 2007-10-25 2010-04-18 Inhalation compositions comprising montelukast acid and a pde - 4 inhibitor or an inhaled corticosteroid IL205182A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32707P 2007-10-25 2007-10-25
PCT/CA2008/001874 WO2009052624A1 (en) 2007-10-25 2008-10-23 Combination therapy

Publications (1)

Publication Number Publication Date
IL205182A0 true IL205182A0 (en) 2010-11-30

Family

ID=40579006

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205182A IL205182A0 (en) 2007-10-25 2010-04-18 Inhalation compositions comprising montelukast acid and a pde - 4 inhibitor or an inhaled corticosteroid

Country Status (19)

Country Link
US (1) US20100210611A1 (enExample)
EP (1) EP2211863A4 (enExample)
JP (1) JP2011500731A (enExample)
KR (1) KR20100072295A (enExample)
CN (1) CN101909626A (enExample)
AU (1) AU2008316283A1 (enExample)
CA (1) CA2701956A1 (enExample)
CO (1) CO6270213A2 (enExample)
CR (1) CR11439A (enExample)
DO (1) DOP2010000122A (enExample)
GT (1) GT201000107A (enExample)
IL (1) IL205182A0 (enExample)
MA (1) MA33705B1 (enExample)
MX (1) MX2010004529A (enExample)
NI (1) NI201000069A (enExample)
NZ (1) NZ584876A (enExample)
RU (1) RU2470639C2 (enExample)
WO (1) WO2009052624A1 (enExample)
ZA (1) ZA201002562B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
EP3096760A1 (en) 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN108267531B (zh) * 2016-12-31 2022-01-11 天津金耀集团有限公司 一种环索奈德有关物质hplc测定方法
IT201900014178A1 (it) * 2019-08-06 2021-02-06 Genetic S P A Esteri del montelukast e loro formulazioni farmaceutiche

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US20040214805A1 (en) * 1999-11-02 2004-10-28 Smithkline Beecham Corporation Method and compositions for treating pulmonary diseases
WO2002038155A1 (en) * 2000-11-07 2002-05-16 Merck & Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
KR20040044946A (ko) * 2001-09-19 2004-05-31 알타나 파마 아게 Pde 억제제와 류코트리엔 수용체 길항제의 병용
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US7553853B2 (en) * 2003-10-10 2009-06-30 Synthon Bv Solid-state montelukast
RU2437658C2 (ru) * 2004-02-06 2011-12-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
CN101175480A (zh) * 2005-03-16 2008-05-07 伊兰制药国际有限公司 纳米微粒白三烯受体拮抗剂/皮质类固醇制剂
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
CA2623882A1 (en) * 2005-09-28 2007-04-05 Merck Frosst Canada Ltd. Aerosol powder formulation comprising sieved lactose

Also Published As

Publication number Publication date
RU2470639C2 (ru) 2012-12-27
CN101909626A (zh) 2010-12-08
CR11439A (es) 2010-06-21
AU2008316283A1 (en) 2009-04-30
US20100210611A1 (en) 2010-08-19
MA33705B1 (fr) 2012-11-01
ZA201002562B (en) 2011-06-29
WO2009052624A9 (en) 2010-11-25
RU2010120806A (ru) 2011-11-27
JP2011500731A (ja) 2011-01-06
WO2009052624A1 (en) 2009-04-30
CO6270213A2 (es) 2011-04-20
DOP2010000122A (es) 2010-07-15
MX2010004529A (es) 2010-05-10
KR20100072295A (ko) 2010-06-30
NZ584876A (en) 2012-06-29
NI201000069A (es) 2010-08-23
EP2211863A1 (en) 2010-08-04
EP2211863A4 (en) 2012-07-25
GT201000107A (es) 2012-03-13
CA2701956A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
IL250937A0 (en) Pharmaceutical preparations and kits containing sphingomyelinase acid
ZA201007239B (en) Ventilation circuit adaptor and proximal aerosol delivery system
GB0621957D0 (en) Inhaler devices and bespoke pharmaceutical compositions
IL194472A0 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
ZA200809002B (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP2101855A4 (en) ADMINISTRATION OF ANTI-THERAPY
AU315301S (en) Respiratory mask
AU311482S (en) Respiratory mask
GB0721739D0 (en) medicinal inhalation devices and components thereof
AU311486S (en) Respiratory mask
AP2008004671A0 (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AU311431S (en) Respiratory mask
AU309800S (en) Respiratory mask
IL195247A0 (en) Inhaler
AU311195S (en) Respiratory mask
IL197025A0 (en) Aerosol formulation for the inhalation of beta agonists
AU311198S (en) Respiratory mask
IL197024A0 (en) Aerosol formulation for the inhalation of beta agonists
EP2205301A4 (en) MEDICAL INHALATION DEVICES AND COMPONENTS THEREOF
PL2121025T3 (pl) Sposoby i kompozycje dla dostarczania czynnika terapeutycznego
GB0701946D0 (en) Inhaler
IL205182A0 (en) Inhalation compositions comprising montelukast acid and a pde - 4 inhibitor or an inhaled corticosteroid
IL200082A0 (en) Metered-dose inhaler
EP2307558A4 (en) COMPOSITIONS AND PROCEDURES FOR THE PROTECTION OF NUCLEOPHILER GROUPS
GB2461008B (en) Nicotine inhalation device